Ad
Search
Generic filters
Filter by content type
Taxonomy terms

XLO – Xilio Therapeutics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.8

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 28

Low: 20

High: 36

Total Analysts: 5

Company Profile

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built its geographically precise solutions (GPS) platform to rapidly engineer molecules, including cytokines and other biologics. The Company’s most advanced product candidates are in clinical development. Its XTX101 is a clinical-stage, tumor-selective anti-CTLA-4 mAb, which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by localizing its activity in the TME. It initiated a Phase I/II trial to evaluate XTX101 in patients with advanced solid tumors, and enrollment is ongoing. XTX202 is an engineered form of IL-2, which is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by TME-associated proteases. It initiated a Phase I/II trial to evaluate XTX202 in patients with solid tumors.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses